Business Wire

FXCM Pro Announces Liquidity Bridging Partnership With Tools for Brokers

5.9.2023 11:00:00 EEST | Business Wire | Press release

Share

FXCM Pro, the institutional arm of FXCM, a leading international provider of online foreign exchange trading, CFD trading and related services has announced a liquidity bridging partnership with Tools for Brokers (TFB), an international technology provider for retail brokers, prop trading companies, and hedge funds.

FXCM Pro will be streaming its institutional liquidity directly to TFB clients, enabling them to connect pricing and trading to their MT4 and MT5 platforms using TFB’s FIX API server. With this new partnership, FXCM Pro’s clients will benefit from having an additional option when selecting a technology/bridge provider.

TFB’s Trade Processor bridge works with the MT4 and MT5, cTrader, Match-Trader, and other platforms and supports third-party integrations via external FIX API. Additionally, it provides brokers with data analysis and enhanced risk management, all through a simple, user-friendly interface.

Mario Sanchez, Managing Director and Global Head of FXCM Pro Sales, commented: “At FXCM Pro, we are committed to providing our clients with the technology they need to succeed, and this is demonstrated in our partnership with Tools for Brokers. This collaboration gives our clients additional choice when it comes to selecting a bridging provider and by selecting TFB, they will benefit from fast execution, automation and improved market access.”

Alexey Kutsenko, CEO at Tools for Brokers, said, “We are excited to partner with FXCM Pro. Under the partnership, FXCM Pro’s clients will benefit from advanced and fast execution without compromising quality or security. Combining our experience and expertise will create a strong platform for many brokerages and hedge funds, allowing them to scale faster and more sustainably.”

FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime. Its relationships with tier 1 banks and non-bank liquidity providers, prime broker relationships and technology vendors provide clients with best-in-class market access.

Tools for Brokers (TFB) is an international technology provider for retail brokers, prop trading companies, and hedge funds operating on multiple platforms, including MetaTrader, Match-Trader, and cTrader. It offers an ecosystem of solutions centred around the flagship Trade Processor liquidity bridge, supported by data management and reporting, money management, and a single web-user interface for individual solutions’ management.

For more information on FXCM, please visit http://www.fxcm.com/

For more information on TFB, please visit https://t4b.com/

###

Disclaimers:

This communication is intended for institutional and professional clients only.

About FXCM:

FXCM is a leading provider of online foreign exchange (FX) trading, CFD trading, and related services. Founded in 1999, the company's mission is to provide global traders with access to the world's largest and most liquid market by offering innovative trading tools, hiring excellent trading educators, meeting strict financial standards, and striving for the best online trading experience in the market. Clients have the advantage of mobile trading, one-click order execution and trading from real-time charts. In addition, FXCM offers educational courses on FX trading and provides trading tools, proprietary data and premium resources. FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime.

About Tools for Brokers:

Tools for Brokers (TFB) is a multiplatform technology provider for retail brokers, prop trading companies, and hedge funds with solutions operating on MetaTrader, Match-Trader, and cTrader. The ecosystem of products centers around the Trade Processor liquidity bridge, enhanced with data management and reporting functionality, TFB PAMM for money management, and the TFB Toolbox — a single web-user interface for individual custom solutions’ management. The flagship multiplatform liquidity bridge solution — Trade Processor — supports a pool of liquidity providers, helps clients manage risks, collects data, and automates the most critical processes all through a single console.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

FXCM Media contact:
Chatsworth Communications
+44 (0) 20 7440 9780
fxcm@chatsworthcommunications.com

Tools for Brokers contact:
Yulia Ogorodnikova
y.ogorodnikova@t4b.com
Tel: +447503599088

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye